FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130078082> ?p ?o ?g. }

• W2130078082 endingPage "870" @default.
• W2130078082 startingPage "864" @default.
• W2130078082 abstract "Patients with nonresectable metastatic neuroendocrine tumors (NETs) experience symptoms of hormone hypersecretion including diarrhea, flushing, and bronchoconstriction, which can interfere with quality of life [Anthony and Vinik (2011) Pancreas, 40:987]. Treatment with a long-acting release formulation of octreotide, a somatostatin analog, can help to alleviate these symptoms. Although high doses of octreotide are often required for adequate symptom control, the relationship between octreotide dose escalation and symptom control in the NET context is not well quantified in the literature. A retrospective chart review was conducted of nonresectable metastatic NET patients who received a dose greater than 30 mg intramuscular octreotide long-acting formulation (O-LAR) at any time between January 2005 and December 2011 at the British Columbia Cancer Agency (BCCA). The association between dose escalation of O-LAR, chromogranin A (CGA), 24-h urine 5-hydoxyindoacetate (5-HIAA), symptom control, and radiological progression was explored. Dose escalation of O-LAR was associated with improved symptom control in NET patients who were refractory to the standard dose levels. Reduction of serum CGA & 5-HIAA levels by at least 10% was observed in 31% and 23% respectively. Retrospective review of imaging did not document any reductions in tumor volume. Higher doses of O-LAR are associated with improved symptom control in NET patients. The variability in tumor marker levels in response to O-LAR dose escalation may indicate that tumor marker levels may not be an accurate assessment of therapeutic efficacy." @default.
• W2130078082 created "2016-06-24" @default.
• W2130078082 creator A5011288790 @default.
• W2130078082 creator A5013037640 @default.
• W2130078082 creator A5053138163 @default.
• W2130078082 date "2015-02-26" @default.
• W2130078082 modified "2023-09-26" @default.
• W2130078082 title "Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors" @default.
• W2130078082 cites W145149749 @default.
• W2130078082 cites W1534718635 @default.
• W2130078082 cites W1971397093 @default.
• W2130078082 cites W1973304341 @default.
• W2130078082 cites W1977568922 @default.
• W2130078082 cites W1982949335 @default.
• W2130078082 cites W1984292444 @default.
• W2130078082 cites W1990509102 @default.
• W2130078082 cites W1993421446 @default.
• W2130078082 cites W2002962269 @default.
• W2130078082 cites W2011739365 @default.
• W2130078082 cites W2014971874 @default.
• W2130078082 cites W2030545609 @default.
• W2130078082 cites W2045771679 @default.
• W2130078082 cites W2053293468 @default.
• W2130078082 cites W2063862702 @default.
• W2130078082 cites W2065782378 @default.
• W2130078082 cites W2069387784 @default.
• W2130078082 cites W2107392208 @default.
• W2130078082 cites W2107436826 @default.
• W2130078082 cites W2135049144 @default.
• W2130078082 cites W2136767389 @default.
• W2130078082 cites W2136817110 @default.
• W2130078082 cites W2137142564 @default.
• W2130078082 cites W2147448522 @default.
• W2130078082 cites W2149214723 @default.
• W2130078082 cites W2157559498 @default.
• W2130078082 cites W2171026060 @default.
• W2130078082 cites W2337135362 @default.
• W2130078082 cites W54518304 @default.
• W2130078082 doi "https://doi.org/10.1002/cam4.435" @default.
• W2130078082 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4472209" @default.
• W2130078082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25727756" @default.
• W2130078082 hasPublicationYear "2015" @default.
• W2130078082 type Work @default.
• W2130078082 sameAs 2130078082 @default.
• W2130078082 citedByCount "36" @default.
• W2130078082 countsByYear W21300780822015 @default.
• W2130078082 countsByYear W21300780822016 @default.
• W2130078082 countsByYear W21300780822017 @default.
• W2130078082 countsByYear W21300780822018 @default.
• W2130078082 countsByYear W21300780822019 @default.
• W2130078082 countsByYear W21300780822020 @default.
• W2130078082 countsByYear W21300780822021 @default.
• W2130078082 countsByYear W21300780822022 @default.
• W2130078082 countsByYear W21300780822023 @default.
• W2130078082 crossrefType "journal-article" @default.
• W2130078082 hasAuthorship W2130078082A5011288790 @default.
• W2130078082 hasAuthorship W2130078082A5013037640 @default.
• W2130078082 hasAuthorship W2130078082A5053138163 @default.
• W2130078082 hasBestOaLocation W21300780821 @default.
• W2130078082 hasConcept C121332964 @default.
• W2130078082 hasConcept C126322002 @default.
• W2130078082 hasConcept C142424586 @default.
• W2130078082 hasConcept C151730666 @default.
• W2130078082 hasConcept C204232928 @default.
• W2130078082 hasConcept C2776297358 @default.
• W2130078082 hasConcept C2779066768 @default.
• W2130078082 hasConcept C2779343474 @default.
• W2130078082 hasConcept C2781025020 @default.
• W2130078082 hasConcept C71924100 @default.
• W2130078082 hasConcept C77231918 @default.
• W2130078082 hasConcept C86803240 @default.
• W2130078082 hasConcept C87355193 @default.
• W2130078082 hasConcept C90924648 @default.
• W2130078082 hasConceptScore W2130078082C121332964 @default.
• W2130078082 hasConceptScore W2130078082C126322002 @default.
• W2130078082 hasConceptScore W2130078082C142424586 @default.
• W2130078082 hasConceptScore W2130078082C151730666 @default.
• W2130078082 hasConceptScore W2130078082C204232928 @default.
• W2130078082 hasConceptScore W2130078082C2776297358 @default.
• W2130078082 hasConceptScore W2130078082C2779066768 @default.
• W2130078082 hasConceptScore W2130078082C2779343474 @default.
• W2130078082 hasConceptScore W2130078082C2781025020 @default.
• W2130078082 hasConceptScore W2130078082C71924100 @default.
• W2130078082 hasConceptScore W2130078082C77231918 @default.
• W2130078082 hasConceptScore W2130078082C86803240 @default.
• W2130078082 hasConceptScore W2130078082C87355193 @default.
• W2130078082 hasConceptScore W2130078082C90924648 @default.
• W2130078082 hasIssue "6" @default.
• W2130078082 hasLocation W21300780821 @default.
• W2130078082 hasLocation W21300780822 @default.
• W2130078082 hasLocation W21300780823 @default.
• W2130078082 hasLocation W21300780824 @default.
• W2130078082 hasOpenAccess W2130078082 @default.
• W2130078082 hasPrimaryLocation W21300780821 @default.
• W2130078082 hasRelatedWork W105130885 @default.
• W2130078082 hasRelatedWork W1968842095 @default.
• W2130078082 hasRelatedWork W210128691 @default.
• W2130078082 hasRelatedWork W2122972388 @default.

• next